Literature DB >> 9557692

The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes.

R J Johnson1, M Stack, S A Hazlewood, M Jones, C G Blackmore, L F Hu, M Rowe.   

Abstract

One group of sequence variants of Epstein-Barr virus is characterized by a 10-amino-acid deletion within the CTAR-2 functional domain of the latent membrane protein, LMP1. A role for this deletion in enhancing the tumorigenicity of the viral oncogene in rodent fibroblasts was recently demonstrated. We examined the effect of this deletion upon LMP1 function in four human lymphoid cell lines by using three natural variants of LMP1: the prototype B95.8 gene and the CAO and AG876 genes, both of which have codons 343 to 352 of the B95.8-LMP1 deleted. These experiments revealed that LMP1-mediated upregulation of CD40 and CD54 was markedly impaired (by 60 to 90%) with CAO-LMP1 compared with B95.8-LMP1. In contrast, the function of AG876-LMP1 was indistinguishable from that of B95.8-LMP1 in two lines and was only slightly impaired in the other two lines. Activation of NF-kappaB by CAO-LMP1 was not impaired in any of the lines; rather, activation of an NF-kappaB reporter by CAO-LMP1 was consistently about twofold greater than the activation with B95.8- or AG876-LMP1. Therefore, while the CAO-LMP1 is functionally distinct from the prototype B95.8-LMP1 in human lymphocytes, the 10-amino-acid deletion appears not to be directly responsible. This conclusion was confirmed by using a B95.8-LMP1 mutant with codons 343 to 352 deleted and chimerae of CAO- and B95.8-LMP1 in which the CTAR-2 domains of these genes were exchanged. Sequences outside the CTAR-2 domain were implicated in the distinct functional characteristics of CAO-LMP1 in human lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557692      PMCID: PMC109632          DOI: 10.1128/JVI.72.5.4038-4048.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

2.  Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1.

Authors:  R K Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.

Authors:  D W Kingma; W B Weiss; E S Jaffe; S Kumar; K Frekko; M Raffeld
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

5.  HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes.

Authors:  F Bachelerie; J Alcami; F Arenzana-Seisdedos; J L Virelizier
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

6.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Authors:  O Devergne; E Hatzivassiliou; K M Izumi; K M Kaye; M F Kleijnen; E Kieff; G Mosialos
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population.

Authors:  M L Chen; C N Tsai; C L Liang; C H Shu; C R Huang; D Sulitzeanu; S T Liu; Y S Chang
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

8.  Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1.

Authors:  M Peng; E Lundgren
Journal:  Leukemia       Date:  1993-01       Impact factor: 11.528

9.  Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas.

Authors:  K Sandvej; S C Peh; B S Andresen; G Pallesen
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

10.  All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts.

Authors:  R K Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more
  18 in total

Review 1.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

2.  Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site.

Authors:  K Sandvej; B S Andresen; X G Zhou; N Gregersen; S Hamilton-Dutoit
Journal:  Mol Pathol       Date:  2000-10

3.  Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia.

Authors:  Jacqueline M Burrows; Lindell Bromham; Megan Woolfit; Gwenaël Piganeau; Judy Tellam; Geoff Connolly; Natasha Webb; Leith Poulsen; Leanne Cooper; Scott R Burrows; Denis J Moss; Sofia M Haryana; Mun Ng; John M Nicholls; Rajiv Khanna
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.

Authors:  Olivia L Hatton; Aleishia Harris-Arnold; Steven Schaffert; Sheri M Krams; Olivia M Martinez
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

7.  Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors.

Authors:  M Higuchi; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

8.  The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.

Authors:  K M Izumi; E D Cahir McFarland; E A Riley; D Rizzo; Y Chen; E Kieff
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines.

Authors:  Satoru Kondo; Naohiro Wakisaka; Masamichi Muramatsu; Yoh Zen; Kazuhira Endo; Shigeyuki Murono; Hisashi Sugimoto; Shoji Yamaoka; Joseph S Pagano; Tomokazu Yoshizaki
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

10.  Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.

Authors:  Maria Vaysberg; Olivia Hatton; Stacie L Lambert; Andrew L Snow; Bonnie Wong; Sheri M Krams; Olivia M Martinez
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.